Quercetin-3-oleoyl derivatives as new GPR40 agonists: Molecular docking studies and functional evaluation

Bioorganic and Medicinal Chemistry Letters

Volumn 29, Issue 14, 2019, Pages 1761-1764

  Carullo, Gabriele ^a   Perri, Mariarita ^a   Manetti, Fabrizio ^b   Aiello, Francesca ^a   Caroleo, Maria Cristina ^a   Cione, Erika ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

GPR40 allosteric site; Insulin secretion; Oleic acid; Quercetin; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; DC 260126; G PROTEIN COUPLED RECEPTOR 40; PROTEIN INHIBITOR; QUERCETIN 3 OLEATE; QUERCETIN 3 OLEOYL; QUERCETIN DERIVATIVE; UNCLASSIFIED DRUG; QUERCETIN;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; INSULIN RELEASE; MOLECULAR DOCKING; PROTEIN TARGETING; HUMAN; PROCEDURES;

HUMANS; MOLECULAR DOCKING SIMULATION; QUERCETIN;

EID: 85065762017     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2019.05.018     Document Type: Article

References (22)

1. Zimmet, P.Z., Magliano, D.J., Herman, W.H., Shaw, J.E., Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2 (2014), 56–64.
2. Li, Z., Xu, X., Huang, W., Qian, H., Free fatty acid receptor 1 (FFAR1)as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges. Med Res Rev 38:2 (2018), 381–425.
3. Mancini, A.D., Bertrand, G., Vivot, K., et al. Beta-arrestin recruitment and biased agonism at free fatty acid receptor 1. J Biol Chem 290:34 (2015), 21131–21140.
4. Alquier, T., Peyot, M., Latour, M.G., et al. Deletion of GPCR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58 (2009), 2607–2615.
5. Feng, D.D., Luo, Z., Roh, S., et al. Reduction in voltage-gated K currents in primary cultured rat pancreatic-cells by linoleic acids. Endocrinology 147:2 (2006), 674–682.
6. Houze, J.B., Zhu, L., Sun, Y., et al. AMG 837: a potent, orally bioavailable GPCR40 agonist. Bioorg Med Chem Lett 22:2 (2012), 1267–1270.
7. Rodrigues, D.A., de Sena, M., Pinheiro, P., Ferreira, T.T.S.C., Thota, S., Fraga, C.A.M., Structural basis for the agonist action at free fatty acid receptor 1 (FFA1R or GPCR40). Chem Biol Drug Des 91:3 (2018), 668–680.
8. Negoro, N., Sasaki, S., Mikami, S., et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPCR40 agonist. ACS Med Chem Lett 1 (2010), 290–294.
9. Kim, M., Gu, G.J., Koh, Y., et al. Fasiglifam (TAK-875), a G Protein-Coupled Receptor 40 (GPCR40)agonist, may induce hepatotoxicity through reactive oxygen species generation in a GPCR40-dependent manner. Biomol Ther 2018 (2018), 1–9.
10. Badolato, M., Carullo, G., Perri, M., et al. Quercetin/oleic acid-based G-protein-coupled receptor 40 ligands as new insulin secretion modulators. Future Med Chem 9:16 (2017), 1873–1885.
11. Mohammad, S., GPCR40 agonists for the treatment of type 2 diabetes mellitus: benefits and challenges. Curr Drug Targets 17:11 (2016), 1292–1300.
12. Lu, J., Byrne, N., Wang, J., et al. Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPCR40. Nature Struct Mol Biol 24 (2017), 570–577.
13. D'Andrea, G., Quercetin: a flavonol with multifaceted therapeutic applications?. Fitoterapia 106 (2015), 256–271.
14. Carullo, G., Aiello, F., Quercetin-3-oleate. Molbank, 3, 2018, M1006.
15. Vasapollo, P., Cione, E., Luciani, F., Gallelli, L., Generalized intense pruritus during canagliflozin treatment: is it an adverse drug reaction?. Curr Drug Saf 13:1 (2018), 38–40.
16. Sharma, D., Verma, S., Vaidya, S., Kalia, K., Tiwari, V., Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother 108 (2018), 952–962.
17. Ho, J.D., Chau, B., Rodgers, L., et al. Structural basis for GPCR40 allosteric agonism and incretin stimulation. Nat Commun, 9, 2018, 1645.
18. Santos, L.R.B., Rebelato, E., Graciano, M.F.R., Abdulkader, F., Curi, R., Carpinelli, A.R., Oleic acid modulates metabolic substrate channeling during glucose-stimulated insulin secretion via NAD(P)H oxidase. Endocrinology 152:10 (2011), 3614–3621.
19. Srivastava, A., Yano, J., Hirozane, Y., et al. High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513 (2014), 124–127.
20. Müller, K., Faeh, C., Diederich, F., Fluorine in pharmaceuticals: looking beyond intuition. Science 317:5846 (2007), 1881–1886.
21. Morgenthaler, M., Aebi, J.D., Grüninger, F., et al. A fluorine scan of non-peptidic inhibitors of neprilysin: fluorophobic and fluorophilic regions in an enzyme active site. J Fluor Chem. 129:9 (2008), 852–865.
22. Krssak, M., Falk Petersen, K., Dresner, A., et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42 (1999), 113–116.